Dr Paul Anderson, LDN Radio Show 19 May 2017 (LDN, low dose naltrexone)

Dr Paul Anderson, LDN Radio Show 19 May 2017 (LDN, low dose naltrexone) from LDN Research Trust on Vimeo. Dr Paul Anderson shares his Low Dose Naltrexone (LDN) experience on the LDN Radio Show with Linda Elsegood. Dr Paul Anderson started 40 years ago working in medical labs and eventually started up his own lab. […]

Dr Patrick Callas, LDN Radio Show 2016 (LDN, low dose naltrexone)

Dr Patrick Callas, LDN Radio Show 2016 (LDN, low dose naltrexone) from LDN Research Trust on Vimeo. Dr Patrick Callas shares his Low Dose Naltrexone (LDN) experience on the LDN Radio Show with Linda Elsegood. Dr Patrick Callas has his own practice on an island on the West Coast of British Columbia and Canada, a […]

What is the evidence behind potential Low Dose Naltrexone benefits? (News)

What is the evidence behind potential Low Dose Naltrexone benefits? California News Times August 2021 https://californianewstimes.com/what-is-the-evidence-behind-potential-low-dose-naltrexone-benefits/493747/ A great deal of research, scientific studies, and anecdotal reports have addressed the many potential benefits of low dose naltrexone.  A documentary entitled The LDN Story closely examined the evidence behind these benefits. The prescription therapy also provides longevity […]

Pharmacist Mark Mandel, LDN Radio Show (LDN, low dose naltrexone)

Pharmacist Mark Mandel, LDN Radio Show (LDN, low dose naltrexone) from LDN Research Trust on Vimeo. Dr. Mark Mandel, owner of Mark drugs, compounding pharmacy in Illinois, United States shares his experience in prescribing and compounding Low Dose Naltrexone. I first heard about LDN in the mid 1990s. One of my patients husband was using […]

Dr Leonard Weinstock, LDN Radio Show (LDN, low dose naltrexone)

Dr Leonard Weinstock, LDN Radio Show (LDN, low dose naltrexone) from LDN Research Trust on Vimeo. Gastroenterologist Dr Leonard Weinstock shares his Low Dose Naltrexone (LDN) experience on the LDN Radio Show with Linda Elsegood. Dr Leonard Weinstock is from St Louis in Missouri and helps patients with GI Issues and other autoimmune conditions. He first […]

Dr Henry Mannings – England, LDN Radio Show (LDN, low dose naltrexone)

Dr Henry Mannings – England, LDN Radio Show (LDN, low dose naltrexone) from LDN Research Trust on Vimeo. Dr Henry Mannings shares his Low Dose Naltrexone (LDN) and Cancer experience on the LDN Radio Show with Linda Elsegood. Dr Henry Mannings has been prescribing Low Dose Naltrexone (LDN) for over 10 years to his cancer […]

Dr Edmund O’Flaherty, LDN Radio Show (LDN, low dose naltrexone)

Dr Edmund O’Flaherty, LDN Radio Show (LDN, low dose naltrexone) from LDN Research Trust on Vimeo. Dr Edmund O’Flaherty shares his Low Dose Naltrexone (LDN) experience on the LDN Radio Show with Linda Elsegood. Dr Edmund O’Flaherty from Dublin, Ireland first heard of Low Dose Naltrexone (LDN) around 15 years ago and was instantly convinced […]

Solutions for Small Intestinal Bacterial Overgrowth (News)

Solutions for Small Intestinal Bacterial Overgrowth The Epoch Times 23 June 2021 https://www.theepochtimes.com/solutions-for-small-intestinal-bacterial-overgrowth_3783088.html A potential cause of SIBO is the decreased activity of the migrating motor complex or a slowing of the gastrointestinal smooth muscle activity. Common prescriptions, including low-dose naltrexone (LDN) and erythromycin, are often successful in activating the migrating motor complex.  

Breast and Colon Cancer by Dr Yusuf Saleeby 2021 (LDN, low dose naltrexone)

Breast and Colon Cancer by Dr Yusuf Saleeby 2021 (LDN, low dose naltrexone) from LDN Research Trust on Vimeo. Dr Yusuf Saleeby: General Preventive and Integrative Medicine/ Restorative Medicine / Functional Medicine, presents on Breast and Colon Cancer. After decades of practicing conventional medicine Dr. Yusuf Saleeby turned to integrative and functional medicine. He shares […]

Inhibition of human colon cancer by intermittent opioid receptor blockade with naltrexone (Abstract)

Inhibition of human colon cancer by intermittent opioid receptor blockade with naltrexone Cancer Lett 29 March 1996 https://pubmed.ncbi.nlm.nih.gov/8620464/ Nude mice inoculated with human colon cancer (HT-29) and receiving 0.1 mg/kg naltrexone (NTX) beginning immediately after tumor cell injection exhibited a marked retardation in tumorigenicity. This dosage of NTX, which blocked opioid receptors for 6-8 h/day, […]